نتائج البحث - "Mesylate therapy"

1

رسالة جامعية

Evaluation Of Response To Imatinib Mesylate Therapy Among Chronic Myeloid Leukaemia Patients As Seen In Nairobi, Kenya

المؤلفون: Yatich, Robert K

مصطلحات موضوعية: matinib Mesylate Therapy Among Chronic Myeloid Leukaemia Patients

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/11295/104732Test

الإتاحة: http://hdl.handle.net/11295/104732Test

View record in BASE

2

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

المؤلفون: Steegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., Garcia-Gutierrez, V., Hochhaus, A., Kim, D-W, Kim, T. D., Khoury, H. J., Le Coutre, P., Mayer, J., Milojkovic, D., Porkka, Kimmo, Rea, D., Rosti, G., Saussele, S., Hehlmann, R., Clark, R. E.

المساهمون: Clinicum, Department of Medicine, Hematologian yksikkö, Department of Oncology

مصطلحات موضوعية: DIAGNOSED CHRONIC-PHASE, DASATINIB 100 MG, PULMONARY ARTERIAL-HYPERTENSION, PATIENTS RECEIVING IMATINIB, CHRONIC MYELOGENOUS LEUKEMIA, CHROMOSOME-POSITIVE LEUKEMIAS, 3122 Cancers, IMATINIB MESYLATE THERAPY, TYROSINE-KINASE INHIBITOR, ACUTE-RENAL-FAILURE, ACUTE LYMPHOBLASTIC-LEUKEMIA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______1593::c1ff7185058c7f2870e202d0527f1f61Test
http://hdl.handle.net/10138/166726Test

3

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

المساهمون: Gugliotta, G, Castagnetti, F, Palandri, F, Breccia, M, Intermesoli, T, Capucci, A, Martino, B, Pregno, P, Rupoli, S, Ferrero, D, Gherlinzoni, F, Montefusco, E, Bocchia, M, Tiribelli, M, Pierri, I, Grifoni, F, Marzocchi, G, Amabile, M, Testoni, N, Martinelli, G, Alimena, G, Pane, Fabrizio, Saglio, G, Baccarani, M, Rosti, G, Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working, Party, Gugliotta G., Castagnetti F., Palandri F., Breccia M., Intermesoli T., Capucci A., Martino B., Pregno P., Rupoli S., Ferrero D., Gherlinzoni F., Montefusco E., Bocchia M., Tiribelli M., Pierri I., Grifoni F., Marzocchi G., Amabile M., Testoni N., Martinelli G., Alimena G., Pane F., Saglio G., Baccarani M., Rosti G.

المصدر: Blood. 117:5591-5599

مصطلحات موضوعية: Myeloid, Male, chronic myeloid leukemia, imatinib, elderly, Biochemistry, Piperazines, hemic and lymphatic diseases, 80 and over, Young adult, Aged, 80 and over, Leukemia, Mortality rate, Myeloid leukemia, Hematology, Middle Aged, Phase III as Topic, Survival Rate, Treatment Outcome, Benzamides, Leukemia, Myeloid, Chronic-Phase, Disease Progression, Imatinib Mesylate, Female, Complete Hematologic Response, Adult, medicine.medical_specialty, Adolescent, Immunology, Alpha interferon, Antineoplastic Agents, Young Adult, Clinical Trials, Phase II as Topic, Internal medicine, medicine, Humans, Clinical Trials, bone-marrow-transplantation, chronic myelogenous leukemia, complete cytogenetic response, early chronic phase, elderly-patients, european-leukemianet, interferon-alpha, line treatment, mesylate therapy, patients receiving imatinib, Survival rate, Aged, business.industry, Clinical Trials, Phase III as Topic, Health Surveys, Pyrimidines, Phase II as Topic, Cell Biology, medicine.disease, Surgery, Imatinib mesylate, Chronic-Phase, business, CHRONIC MYELOID LEUKEMIA (CML), Chronic myelogenous leukemia

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11417cdb4fc08a000cdc878572de7ac4Test
https://doi.org/10.1182/blood-2010-12-324228Test

4

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

المساهمون: Roberto Latagliata, Dario Ferrero, Alessandra Iurlo, Francesco Cavazzini, Fausto Castagnetti, Elisabetta Abruzzese, Carmen Fava, Massimo Breccia, Mario Annunziata, Fabio Stagno, Mario Tiribelli, Gianni Binotto, Giovanna Mansueto, Antonella Gozzini, Sabina Russo, Laura Cavalli, Enrico Montefusco, Gabriele Gugliotta, Michele Cedrone, Antonella Russo Rossi, Paolo Avanzini, Patrizia Pregno, Endri Mauro, Antonio Spadea, Francesca Celesti, Gianfranco Giglio, Alessandro Isidori, Monica Crugnola, Elisabetta Calistri, Federica Sorà, Stefano Storti, Ada D’Addosio, Giovanna Rege-Cambrin, Luigiana Luciano, Giuliana Alimena

المصدر: Drugsaging. 30(8)

مصطلحات موضوعية: Myeloid, Male, Aging, PROGNOSTIC SCORE, TYROSINE KINASE, Comorbidity, Gastroenterology, Piperazines, Cohort Studies, Interquartile range, Pharmacology (medical), Geriatrics and Gerontology, hemic and lymphatic diseases, 80 and over, Medicine, chronic myelogenous leukemm, Aged, 80 and over, education.field_of_study, Leukemia, CHRONIC MYELOGENOUS LEUKEMIA, Remission Induction, Imatinib mesylate, elderly, Tolerability, Italy, Benzamides, Leukemia, Myeloid, Chronic-Phase, Imatinib Mesylate, Female, Drug, Drug Monitoring, Complete Hematologic Response, CLINICAL-TRIALS, medicine.drug, CHRONIC MYELOGENOUS LEUKEMIA, CML WORKING PARTY, MYELOPROLIFERATIVE DISORDERS, INTERFERON-ALPHA, MESYLATE THERAPY, PROGNOSTIC SCORE, TYROSINE KINASE, CLINICAL-TRIALS, FOLLOW-UP, AGE, MESYLATE THERAPY, medicine.medical_specialty, Population, Socio-culturale, Antineoplastic Agents, CML WORKING PARTY, Dose-Response Relationship, AGE, Internal medicine, Humans, education, Protein Kinase Inhibitors, Aged, Retrospective Studies, Dose-Response Relationship, Drug, business.industry, Imatinib, Retrospective cohort study, Survival Analysis, Settore MED/15 - MALATTIE DEL SANGUE, Pyrimidines, Concomitant, Immunology, Chronic-Phase, MYELOPROLIFERATIVE DISORDERS, INTERFERON-ALPHA, Neoplasm Grading, business, FOLLOW-UP, CHRONIC MYELOID LEUKEMIA (CML), Follow-Up Studies

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2a5999de8c0e69be3e94b6f5abaf98bTest
https://pubmed.ncbi.nlm.nih.gov/23681399Test

5

دورية أكاديمية

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.

المؤلفون: Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, Fava C, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Storti S, D'Addosio A, Rege Cambrin G, Luciano L, MONTEFUSCO, Enrico, ALIMENA, Giuliana

المساهمون: Latagliata, R, Ferrero, D, Iurlo, A, Cavazzini, F, Castagnetti, F, Abruzzese, E, Fava, C, Breccia, M, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Mansueto, G, Gozzini, A, Russo, S, Cavalli, L, Montefusco, Enrico, Gugliotta, G, Cedrone, M, Russo Rossi, A, Avanzini, P, Pregno, P, Mauro, E, Spadea, A, Celesti, F, Giglio, G, Isidori, A, Crugnola, M, Calistri, E, Sorà, F, Storti, S, D'Addosio, A, Rege Cambrin, G, Luciano, L, Alimena, Giuliana

مصطلحات موضوعية: CHRONIC MYELOGENOUS LEUKEMIA, CML WORKING PARTY, MYELOPROLIFERATIVE DISORDERS, INTERFERON-ALPHA, MESYLATE THERAPY, PROGNOSTIC SCORE, TYROSINE KINASE, CLINICAL-TRIALS, FOLLOW-UP, AGE

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/23681399; info:eu-repo/semantics/altIdentifier/wos/WOS:000322014600005; volume:30; issue:8; firstpage:629; lastpage:637; numberofpages:9; journal:DRUGS & AGING; http://hdl.handle.net/11573/561442Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84880850549

الإتاحة: https://doi.org/10.1007/s40266-013-0088-6Test
http://hdl.handle.net/11573/561442Test

View record in BASE

6

دورية أكاديمية

Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia

المؤلفون: Laura Cannella, Giuseppina Loglisci, Mauro Nanni, M. r. De Cuia, Gioia Colafigli, Adriano Salaroli, Alessandra Serrao, Massimo Breccia, ALIMENA, Giuliana

المساهمون: Laura, Cannella, Giuseppina, Loglisci, Mauro, Nanni, De Cuia, M. r., Gioia, Colafigli, Adriano, Salaroli, Serrao, Alessandra, Alimena, Giuliana, Massimo, Breccia

مصطلحات موضوعية: abnormalitie, chronic-phase, dasatinib therapy, hematopoiesi, mesylate therapy

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/21854086; info:eu-repo/semantics/altIdentifier/wos/WOS:000300451100027; volume:53; issue:3; firstpage:497; lastpage:498; numberofpages:2; journal:LEUKEMIA & LYMPHOMA; http://hdl.handle.net/11573/404659Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84857515571; http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000300451100027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0c7ff228ccbaaa74236f48834a34396aTest; http://www.scopus.com/inward/record.url?eid=2-s2.0-84857515571&partnerID=65&md5=37d8e7e1b0f896bfc34dc44406327bbeTest

الإتاحة: https://doi.org/10.3109/10428194.2011.615425Test
http://hdl.handle.net/11573/404659Test
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000300451100027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0c7ff228ccbaaa74236f48834a34396aTest
http://www.scopus.com/inward/record.url?eid=2-s2.0-84857515571&partnerID=65&md5=37d8e7e1b0f896bfc34dc44406327bbeTest

View record in BASE

7

دورية أكاديمية

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

المساهمون: Roberto, Latagliata, Massimo, Breccia, Fausto, Castagnetti, Fabio, Stagno, L., Luciano, Antonella, Gozzini, Stefano, Ulisciani, Francesco, Cavazzini, Mario, Annunziata, Federica, Sora, Antonella Russo, Rossi, Patrizia, Pregno, Montefusco, Enrico, Elisabetta, Abruzzese, Elena, Crisa, Pellegrino, Musto, Mario, Tiribelli, Gianni, Binotto, Ubaldo, Occhini, Costanzo, Feo, Paolo, Vigneri, Valeria, Santini, Carmen, Fava, Giannantonio, Rosti, Alimena, Giuliana

مصطلحات موضوعية: age, bcr-abl, chronic myelogenous leukemia, chronic myeloid leukaemia, chronic-phase, clinical-trial, cml, dasatinib, elderly, follow-up, mesylate therapy, resistance, safety, safety durable cytogenetic responses

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/21705080; info:eu-repo/semantics/altIdentifier/wos/WOS:000293778200025; volume:35; issue:9; firstpage:1164; lastpage:1169; numberofpages:6; journal:LEUKEMIA RESEARCH; http://hdl.handle.net/11573/404741Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-80051471275; http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000293778200025&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0c7ff228ccbaaa74236f48834a34396aTest; http://www.ncbi.nlm.nih.gov/pubmed/21705080Test; http://www.scopus.com/inward/record.url?eid=2-s2.0-80051471275&partnerID=65&md5=f039d9417deaab76ede5f7493d573696Test

الإتاحة: https://doi.org/10.1016/j.leukres.2011.05.015Test
http://hdl.handle.net/11573/404741Test
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000293778200025&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0c7ff228ccbaaa74236f48834a34396aTest
http://www.ncbi.nlm.nih.gov/pubmed/21705080Test
http://www.scopus.com/inward/record.url?eid=2-s2.0-80051471275&partnerID=65&md5=f039d9417deaab76ede5f7493d573696Test

View record in BASE

8

دورية أكاديمية

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

المساهمون: G., Gugliotta, F., Castagnetti, F., Palandri, M., Breccia, T., Intermesoli, A., Capucci, B., Martino, P., Pregno, S., Rupoli, D., Ferrero, F., Gherlinzoni, E., Montefusco, M., Bocchia, M., Tiribelli, I., Pierri, F., Grifoni, G., Marzocchi, M., Amabile, N., Testoni, Martinelli, Giovanni, Alimena, Giuliana, F., Pane, G., Saglio, M., Baccarani, Rosti G., Gruppo Italiano Malattie Ematologiche Dell'Adulto Cml Working Party

مصطلحات موضوعية: bone-marrow-transplantation, chronic myelogenous leukemia, complete cytogenetic response, early chronic phase, elderly-patient, european-leukemianet, interferon-alpha, line treatment, mesylate therapy, patients receiving imatinib

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/21450900; info:eu-repo/semantics/altIdentifier/wos/WOS:000291010500009; volume:117; issue:21; firstpage:5591; lastpage:5599; numberofpages:9; journal:BLOOD; http://hdl.handle.net/11573/405409Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-79957588158; http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000291010500009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0c7ff228ccbaaa74236f48834a34396aTest; http://www.ncbi.nlm.nih.gov/pubmed/21450900Test; http://www.scopus.com/inward/record.url?eid=2-s2.0-79957588158&partnerID=65&md5=2f065ee1d211d86e2fbc6688ee940baeTest

الإتاحة: https://doi.org/10.1182/blood-2010-12-324228Test
http://hdl.handle.net/11573/405409Test
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000291010500009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0c7ff228ccbaaa74236f48834a34396aTest
http://www.ncbi.nlm.nih.gov/pubmed/21450900Test
http://www.scopus.com/inward/record.url?eid=2-s2.0-79957588158&partnerID=65&md5=2f065ee1d211d86e2fbc6688ee940baeTest

View record in BASE

9

دورية أكاديمية

Factors influencing a second myeloid malignancy in patients with Philadelphia-negative-7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia

المؤلفون: Groves, Michael J., Sales, Mark, Baker, Lee, Griffiths, Michael, Pratt, Norman, Tauro, Sudhir

المصدر: Groves , M J , Sales , M , Baker , L , Griffiths , M , Pratt , N & Tauro , S 2011 , ' Factors influencing a second myeloid malignancy in patients with Philadelphia-negative-7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia ' , Cancer Genetics , vol. 204 , no. 1 , pp. 39-44 . https://doi.org/10.1016/j.cancergencyto.2010.08.017Test

مصطلحات موضوعية: del(7q), tyrosine kinase inhibitor, MDS, AML, CML, Philadelphia negative, CHRONIC MYELOGENOUS LEUKEMIA, CHROMOSOME-NEGATIVE CELLS, IMATINIB MESYLATE THERAPY, COMPLETE CYTOGENETIC RESPONSE, CHRONIC MYELOCYTIC-LEUKEMIA, CHRONIC PHASE, CML PATIENTS, INTERFERON-ALPHA, ABNORMAL CLONES, PH-CELLS

العلاقة: https://discovery.dundee.ac.uk/en/publications/848d6479-b582-4264-ad38-f921a27b5cbaTest

الإتاحة: https://doi.org/10.1016/j.cancergencyto.2010.08.017Test
https://discovery.dundee.ac.uk/en/publications/848d6479-b582-4264-ad38-f921a27b5cbaTest

View record in BASE

10

دورية أكاديمية

FIP1L1-PDGFR alpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFR alpha T674I eosinophilic leukemia with single agent sorafenib

المؤلفون: Lierman, Els, Michaux, Lucienne, Beullens, Els, Pierre, P, Marynen, Peter, Cools, Jan, Vandenberghe, Peter

مصطلحات موضوعية: kinase inhibitor, resistance, eosinophilia, oncogene, tyrosine kinase, idiopathic hypereosinophilic syndrome, gastrointestinal stromal tumor, imatinib mesylate therapy, chronic myeloid-leukemia, renal-cell carcinoma, myeloproliferative disease, molecular remission, tyrosine kinases, pdgfr-beta

العلاقة: Leukemia vol:23 issue:5 pages:845-851; https://lirias.kuleuven.be/handle/123456789/241073Test

الإتاحة: https://lirias.kuleuven.be/handle/123456789/241073Test

View record in BASE

النص الكامل

تنقيح النتائج